{"filing":{"accession_number":"0001193125-26-398015","cik":"0001159036","ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"d148460d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm"},"events":[{"id":34361,"run_id":31620,"accession_number":"0001193125-26-398015","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Halozyme completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, with net proceeds of approximately $1,471.1 million intended for debt repurchases, general corporate purposes, and potential acquisitions. The convertible notes are convertible into up to 13,676,100 shares of common stock at a conversion rate of 9.1174 shares per $1,000 principal amount, creating both a direct financial obligation and potential equity dilution.","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":38061,"accession_number":"0001193125-26-398015","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Halozyme completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, pursuant to an indenture with The Bank of New York Mellon Trust Company, N.A. This is a material debt issuance creating a direct financial obligation. The company received net proceeds of approximately $1,471.1 million and intends to use proceeds for debt repurchases, general corporate purposes, and potential acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38062,"accession_number":"0001193125-26-398015","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 is the standard disclosure location for creation of direct financial obligations such as debt issuance, credit facilities, or term loans. The incorporation by reference to Item 1.01 (Business Combinations) suggests this may involve debt incurred in connection with an acquisition or material transaction. Without access to Item 1.01 details, debt_issuance is the most likely classification for Item 2.03 disclosures, and such obligations are typically material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38063,"accession_number":"0001193125-26-398015","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities in the form of convertible notes with a maximum of 13,676,100 shares of common stock issuable upon conversion at a conversion rate of 9.1174 shares per $1,000 principal amount. This is a classic dilutive issuance involving convertible debt that creates potential equity dilution to existing shareholders, material to investor assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38061,"accession_number":"0001193125-26-398015","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Halozyme completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, pursuant to an indenture with The Bank of New York Mellon Trust Company, N.A. This is a material debt issuance creating a direct financial obligation. The company received net proceeds of approximately $1,471.1 million and intends to use proceeds for debt repurchases, general corporate purposes, and potential acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-09-22"},{"id":38062,"accession_number":"0001193125-26-398015","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 is the standard disclosure location for creation of direct financial obligations such as debt issuance, credit facilities, or term loans. The incorporation by reference to Item 1.01 (Business Combinations) suggests this may involve debt incurred in connection with an acquisition or material transaction. Without access to Item 1.01 details, debt_issuance is the most likely classification for Item 2.03 disclosures, and such obligations are typically material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-09-22"},{"id":38063,"accession_number":"0001193125-26-398015","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities in the form of convertible notes with a maximum of 13,676,100 shares of common stock issuable upon conversion at a conversion rate of 9.1174 shares per $1,000 principal amount. This is a classic dilutive issuance involving convertible debt that creates potential equity dilution to existing shareholders, material to investor assessment of ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:42:47.777314+00:00","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-09-22"}]}